
|Videos|September 8, 2022
What’s next for Black-tailored prostate cancer risk calculator?
Author(s)Urology Times staff
“[With] some folks, if you don't accurately risk stratify them, you miss your chance to really build that trust as a provider,” says Neil Mistry, MD, MPH.
Advertisement
In this video, Neil Mistry, MD, MPH, and Adam B. Murphy, MD, MBA, MSCI, discuss future research and the take-home message from the abstract, “West-African ancestry can aid prediction of high-grade prostate cancer in Black-tailored risk calculator,” which was presented at the North Central Section of the AUA Annual Meeting in Chicago, Illinois. Mistry is a urology resident and Murphy is an assistant professor of urology and preventive medicine (cancer epidemiology and prevention) at Northwestern University Feinberg School of Medicine in Chicago.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
4
EV plus pembro approval reframes first conversation in MIBC diagnosis
5













